pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Welireg
drug · small molecule
save

belzutifan

Marketedupdated 6mo ago
by $MRK Merck & Co., Inc.🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 3 investigational indications.

targets

Endothelial PAS domain-containing protein 1

all catalysts(0)

nothing on the calendar yet

Trials studying belzutifan

  • phase3A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)recruitingn=758
  • phase3A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)active not recruitingn=747
  • phase2A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)active not recruitingn=60
  • phase2A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)recruitingn=15
  • phase2Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)recruitingn=355
  • phase3A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)active not recruitingn=755
  • phase2A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)not yet recruitingn=480
  • phase2A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)completedn=154

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 14, 2026
27 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Jun 30, 2042formulationUS 12358870
  • Sep 5, 2034compositionUS 9908845
  • Sep 5, 2034compositionUS RE49948

FDA exclusivities (4)

  • Aug 13, 2028ODE-364Orphan Drug (7y)1.7y
  • May 14, 2028I-968Indication (3y)1.5y
  • Dec 14, 2026I-931Indication (3y)27d
  • Aug 13, 2026NCENew Chemical Entity (5y)

News(9)

  • Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
    Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…
    fiercebiotech · 19d ago
  • Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
    New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
    biopharma_dive · 26d ago
  • Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
    Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…
    biospace · 1mo ago
  • Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
    Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
    biopharma_dive · 1mo ago
  • Merck expands Welireg's use to broader set of kidney cancer patients
    Merck’s Welireg won FDA approval on Friday for use in combination with Eisai’s Lenvima to treat certain kidney cancer patients. The combination will be available to patients with advanced renal cel…
    endpoints · 1mo ago
  • Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
    biopharma_dive · 3mo ago
  • Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
    The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
    biospace · 3mo ago
  • Merck brings Welireg-Keytruda combo to treat kidney cancer
    Merck’s Welireg and Keytruda combination won approval as an adjuvant treatment for kidney cancer patients after surgery to remove all or part of the organ. The combination was approved Friday for ...
    endpoints · 5mo ago
  • Merck still sees ‘compelling’ outlook for Terns leukemia drug
    Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
    biopharma_dive · 6mo ago
brand
Welireg
trade names
Welireg
generic
belzutifan
MOA
Endothelial PAS domain-containing protein 1 inhibitor
indication
Renal Cell Carcinoma
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?